Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorQueen's Medical Center
About this trial
The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use.
The main objectives are to:
* Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury * To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.
Participants will:
* Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit * Complete Treatment Effectiveness Assessments at 6 and 12-weeks * Engage in a qualitative interview at the end of the CM program
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Admitted trauma patients
Age greater than 18 years old
Urine drug screen positive for methamphetamines during the current hospitalization
Report at least weekly methamphetamine use
Disqualifiers
Active psychosis (reporting auditory or visual hallucinations)
Under ongoing cardiorespiratory monitoring
Evidence of moderate or severe traumatic brain injury
Patients who are known to be pregnant
Trial design
Design model
Single group
Treatments tested in this trial
Contingency Managment
BehavioralIf the sample be methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately, half of the slips offer written praise (e.g. "great job!"). The other half of slips are then divided between low value (e.g. food gift cards, bus passes), medium value (e.g. prepaid cell phone, clothing gift cards), and a few large value rewards (e.g. iPad, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date.
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: Contingency ManagmentExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
TEA Outcomes at 6 and 12-weeks
Treatment Effectiveness Assessment (TEA): This assessment asks individuals to respond to changes in four domains following a drug treatment program: substance use, health, lifestyle, and community. The score for each domain can range from 1 (no change or not much) to 10 (much better), for a total score of 4-40. This score allows for the prioritization of each participants values, and therefore does not require strict abstinence to demonstrate benefit from drug treatment.
Time frame
From enrollment to 6 and 12-weeksSecondary outcomes
1
Qualitative Outcomes
Interviews will be conducted as semi-structured interviews using a priori interview guides. Interviews will be transcribed and analyzed using a Template Analysis approach. Two coders will conduct coding of the interview data to ultimately identify themes that will be used as the basis for interpretation. The final analysis of the qualitative data will include contrasts and comparisons made across interviews to examine overlaps and divergences across any relevant sub-samples (e.g., sex, age). Results will present thematic patterns, how frequently each code occurs, and any contradictory evidence.
Time frame
At the end of treatment at 12-weeksOther outcomes
1
Urine Analysis Results
Study personnel will ask participant to complete a urine analysis screen. Following completion of the urinalysis, study personnel will use a test strip to determine if the sample is methamphetamine negative or positive. Results will be documented and analyzed for a reduction in methamphetamine.
Time frame
From enrollment to the end of treatment at 12-weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Queen's Medical Center
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
Collaborator
Source ClinicalTrials.gov